by Touch Stone Publishers | Jul 22, 2026
The Signal Organon filed a Form 8-K on July 17, 2026, voluntarily supplementing its definitive Sun Pharma merger proxy statement with new synergy, valuation, and board process detail, in direct response to a still pending New Jersey injunction motion aimed at...
by Touch Stone Publishers | Jul 8, 2026
The Signal Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $85.00 per share in an all-cash deal valued at roughly $10 billion, or about $8.8 billion net of estimated cash. The terms, unanimously approved by both boards and disclosed in 8-K...